BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disease causing unpredictable and potentially life-threatening subcutaneous and submucosal edematous attacks. Cinryze® (Shire ViroPharma Inc., Lexington, MA, USA), a nanofiltered C1 inhibitor (C1-INH), is approved in Europe for the treatment, preprocedure prevention, and routine prophylaxis of HAE attacks, and for the routine prophylaxis of attacks in the USA. This phase 3 study assessed the safety and efficacy of 2 C1-INH doses in preventing attacks in children aged 6-11 years. METHODS: A randomized single-blind crossover study was initiated in March 2014. Results for the first 6 patients completing the study are reported here. After a 12-week qualifying observation period, patients were randomly assigned to 1 of 2 C1-INH doses, 500 or 1,000 U, every 3-4 days for 12 weeks and crossed over to the alternative dose for a second 12-week period. The primary efficacy endpoint was the number of angioedema attacks per month. RESULTS:Six females with HAE type I and a median age of 10.5 years received 2 doses of C1-INH (500 and 1,000 U). The mean (SD) difference in the number of monthly angioedema attacks between the baseline observation period and the treatment period was -1.89 (1.31) with 500 U and -1.89 (1.11) with 1,000 U. During the treatment periods, cumulative attack severity, cumulative daily severity, and the number of attacks needing acute treatment were lower. No serious adverse events or study drug discontinuations occurred. CONCLUSIONS: Interim findings from this study indicate that routine prevention with intravenous administration of C1-INH is efficacious, safe, and well tolerated in children ≥6 years of age.
RCT Entities:
BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disease causing unpredictable and potentially life-threatening subcutaneous and submucosal edematous attacks. Cinryze® (Shire ViroPharma Inc., Lexington, MA, USA), a nanofiltered C1 inhibitor (C1-INH), is approved in Europe for the treatment, preprocedure prevention, and routine prophylaxis of HAE attacks, and for the routine prophylaxis of attacks in the USA. This phase 3 study assessed the safety and efficacy of 2 C1-INH doses in preventing attacks in children aged 6-11 years. METHODS: A randomized single-blind crossover study was initiated in March 2014. Results for the first 6 patients completing the study are reported here. After a 12-week qualifying observation period, patients were randomly assigned to 1 of 2 C1-INH doses, 500 or 1,000 U, every 3-4 days for 12 weeks and crossed over to the alternative dose for a second 12-week period. The primary efficacy endpoint was the number of angioedema attacks per month. RESULTS: Six females with HAE type I and a median age of 10.5 years received 2 doses of C1-INH (500 and 1,000 U). The mean (SD) difference in the number of monthly angioedema attacks between the baseline observation period and the treatment period was -1.89 (1.31) with 500 U and -1.89 (1.11) with 1,000 U. During the treatment periods, cumulative attack severity, cumulative daily severity, and the number of attacks needing acute treatment were lower. No serious adverse events or study drug discontinuations occurred. CONCLUSIONS: Interim findings from this study indicate that routine prevention with intravenous administration of C1-INH is efficacious, safe, and well tolerated in children ≥6 years of age.
Authors: Jonathan A Bernstein; Michael E Manning; Henry Li; Martha V White; James Baker; William R Lumry; Mark A Davis-Lorton; Kraig W Jacobson; Richard G Gower; Colin Broom; David Fitts; Jennifer Schranz Journal: J Allergy Clin Immunol Pract Date: 2013-11-11
Authors: Bruce L Zuraw; Paula J Busse; Martha White; Joshua Jacobs; William Lumry; James Baker; Timothy Craig; J Andrew Grant; David Hurewitz; Leonard Bielory; William E Cartwright; Majed Koleilat; Walter Ryan; Oren Schaefer; Michael Manning; Pragnesh Patel; Jonathan A Bernstein; Roger A Friedman; Robert Wilkinson; David Tanner; Gary Kohler; Glenne Gunther; Robyn Levy; James McClellan; Joseph Redhead; David Guss; Eugene Heyman; Brent A Blumenstein; Ira Kalfus; Michael M Frank Journal: N Engl J Med Date: 2010-08-05 Impact factor: 91.245
Authors: William Lumry; Michael E Manning; David S Hurewitz; Mark Davis-Lorton; David Fitts; Ira N Kalfus; Marc E Uknis Journal: J Pediatr Date: 2013-01-11 Impact factor: 4.406
Authors: Emel Aygören-Pürsün; Daniel F Soteres; Sandra A Nieto-Martinez; Jim Christensen; Kraig W Jacobson; Dumitru Moldovan; Arthur Van Leerberghe; Yongqiang Tang; Peng Lu; Moshe Vardi; Jennifer Schranz; Inmaculada Martinez-Saguer Journal: Pediatr Allergy Immunol Date: 2019-05-29 Impact factor: 6.377
Authors: Stephen Betschel; Jacquie Badiou; Karen Binkley; Rozita Borici-Mazi; Jacques Hébert; Amin Kanani; Paul Keith; Gina Lacuesta; Susan Waserman; Bill Yang; Emel Aygören-Pürsün; Jonathan Bernstein; Konrad Bork; Teresa Caballero; Marco Cicardi; Timothy Craig; Henriette Farkas; Anete Grumach; Connie Katelaris; Hilary Longhurst; Marc Riedl; Bruce Zuraw; Magdelena Berger; Jean-Nicolas Boursiquot; Henrik Boysen; Anthony Castaldo; Hugo Chapdelaine; Lori Connors; Lisa Fu; Dawn Goodyear; Alison Haynes; Palinder Kamra; Harold Kim; Kelly Lang-Robertson; Eric Leith; Christine McCusker; Bill Moote; Andrew O'Keefe; Ibraheem Othman; Man-Chiu Poon; Bruce Ritchie; Charles St-Pierre; Donald Stark; Ellie Tsai Journal: Allergy Asthma Clin Immunol Date: 2019-11-25 Impact factor: 3.406
Authors: Donald Levy; Teresa Caballero; Iftikhar Hussain; Avner Reshef; John Anderson; James Baker; Lawrence B Schwartz; Marco Cicardi; Subhransu Prusty; Henrike Feuersenger; Ingo Pragst; Michael E Manning Journal: Pediatr Allergy Immunol Pulmonol Date: 2020-09-16 Impact factor: 1.349